Correlation Between Barclays Capital and Zenas BioPharma,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Barclays Capital and Zenas BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Barclays Capital and Zenas BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Barclays Capital and Zenas BioPharma, Common, you can compare the effects of market volatilities on Barclays Capital and Zenas BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Barclays Capital with a short position of Zenas BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Barclays Capital and Zenas BioPharma,.

Diversification Opportunities for Barclays Capital and Zenas BioPharma,

-0.06
  Correlation Coefficient

Good diversification

The 3 months correlation between Barclays and Zenas is -0.06. Overlapping area represents the amount of risk that can be diversified away by holding Barclays Capital and Zenas BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zenas BioPharma, Common and Barclays Capital is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Barclays Capital are associated (or correlated) with Zenas BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zenas BioPharma, Common has no effect on the direction of Barclays Capital i.e., Barclays Capital and Zenas BioPharma, go up and down completely randomly.

Pair Corralation between Barclays Capital and Zenas BioPharma,

If you would invest  8,320  in Barclays Capital on September 21, 2024 and sell it today you would earn a total of  0.00  from holding Barclays Capital or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy3.17%
ValuesDaily Returns

Barclays Capital  vs.  Zenas BioPharma, Common

 Performance 
       Timeline  
Barclays Capital 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Barclays Capital has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Barclays Capital is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.
Zenas BioPharma, Common 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Barclays Capital and Zenas BioPharma, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Barclays Capital and Zenas BioPharma,

The main advantage of trading using opposite Barclays Capital and Zenas BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Barclays Capital position performs unexpectedly, Zenas BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will offset losses from the drop in Zenas BioPharma,'s long position.
The idea behind Barclays Capital and Zenas BioPharma, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum